All News

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Xavier Llor, MD, of Yale Medicine, discusses what the updated guidance from the American Cancer Society on colorectal cancer screening mean for primary care.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

New FLOW trial data presented at ERA 2026 showed semaglutide improved health-related quality of life in adults with type 2 diabetes and CKD.

Recent FDA updates include new actions in diabetes, hypertension, chronic HDV infection, bipolar depression, and CKD in type 1 diabetes.

A natural experiment found pediatric influenza vaccination reduced influenza diagnoses among children aged 2 to 5 years.

A national survey found US adults recognize STI transmission routes but remain uncertain about HPV and mpox vaccine prevention.

The FDA today issued a Complete Response Letter for Cingulate’s CTx-1301 for ADHD, citing CMC-related requests and no current safety or efficacy concerns.

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Kohli discusses the FDA approval of baxdrostat (Baxfendy), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

A validated AI phenotyping tool identified chronic long COVID burden missed by ICD surveillance in nearly 460,000 COVID-19 patients.

Elunetirom received FDA Fast Track designation as an adjunctive therapy for bipolar depression, with phase 2 AMPLIFY-BD data expected in 2026.

VERVE-102 reduced PCSK9 and LDL-C after one infusion in early Heart-2 data for patients needing additional lipid lowering.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.